VIRGINIA RETIREMENT SYSTEMS ET Al Invests $3.54 Million in DaVita Inc. $DVA

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of DaVita Inc. (NYSE:DVA) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 15,900 shares of the company’s stock, valued at approximately $3,537,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Root Financial Partners LLC raised its holdings in shares of DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after buying an additional 105 shares during the period. Caitlin John LLC bought a new stake in shares of DaVita during the fourth quarter worth $34,000. Sankala Group LLC bought a new stake in shares of DaVita during the fourth quarter worth $39,000. Canada Pension Plan Investment Board purchased a new stake in shares of DaVita during the second quarter valued at $43,000. Finally, Kestra Advisory Services LLC bought a new position in shares of DaVita in the fourth quarter worth about $45,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on DVA. Raymond James Financial set a $220.00 price target on shares of DaVita in a research note on Friday, August 7th. Oppenheimer set a $220.00 target price on shares of DaVita in a research note on Friday, August 7th. TD Cowen raised shares of DaVita from a “hold” rating to a “buy” rating and lifted their price target for the company from $201.00 to $220.00 in a research note on Friday, August 7th. Barclays boosted their price target on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Finally, Truist Financial reduced their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $233.43.

DaVita Stock Performance

NYSE DVA opened at $183.11 on Thursday. The company has a market cap of $11.68 billion, a PE ratio of 14.98, a P/E/G ratio of 0.47 and a beta of 0.83. The firm’s 50 day moving average price is $206.15 and its 200-day moving average price is $185.25. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.DaVita’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In related news, insider Kathleen Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.90% of the stock is owned by company insiders.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.